The edoc-Server, the insitutional digital repository system of the Robert Koch Institute captures, stores, indexes, preserves, and distributes digital research material. http://edoc.rki.de:80 2026-10-11T06:18:20Z 2026-10-11T06:18:20Z Baddam, Ramani Kumar, Narender Wieler, Lothar H. Kumar Lankapalli, Aditya Ahmed, Niyaz Peacock, Sharon J. http://edoc.rki.de/176904/14034 2026-10-09T17:27:25Z 2018-05-15T00:00:00Z

Author Correction: Analysis of mutations in pncA reveals non-overlapping patterns among various lineages of Mycobacterium tuberculosis Baddam, Ramani; Kumar, Narender; Wieler, Lothar H.; Kumar Lankapalli, Aditya; Ahmed, Niyaz; Peacock, Sharon J.

2018-05-15T00:00:00Z Melidou, Angeliki Broberg, Eva Buda, Silke http://edoc.rki.de/176904/14033 2026-10-09T16:57:26Z 2018-04-21T00:00:00Z

Erratum to “Predominance of influenza A(H3N2) virus genetic subclade 3C.2a1 during an early 2016/17 influenza season in Europe – Contribution of surveillance data from World Health Organization (WHO) European region to the WHO vaccine composition consultation for northern hemisphere 2017/18” [Vaccine 35 (2017) 4828–4835] Melidou, Angeliki; Broberg, Eva; Buda, Silke

2018-04-21T00:00:00Z PharmaLex GmbH, Bad Homburg vor der Höhe http://edoc.rki.de/176904/14032 2026-10-08T14:09:57Z 2026-10-01T00:00:00Z

Epidemiology and Treatment Patterns of Patients with Pancreatic Cancer in Germany: A Retrospective Analysis of Data from 2020-2024 PharmaLex GmbH, Bad Homburg vor der Höhe Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of pancreatic cancers (PC) and is one of the most fatal malignancies. Given the high clinical burden and a poor overall survival of PDAC patients, contemporary population-based data are needed to describe how many patients are affected and how they are treated in routine care in Germany. Because evidence on treatment sequencing remains limited, real-world data can help clarify which therapies are used and, for systemic therapy, which substances are used across treatment lines. The aim of this study is to assess the prevalence and incidence of PC in Germany, including the distribution of pancreatic cancer types, as well as to analyze real-world treatment patterns among patients with PDAC. The specific study objectives are: - To estimate the incidence and prevalence of PC leveraging nationwide cancer registry data (ZfKD) from Germany - To describe the distribution of pancreatic cancer types and estimate the proportion PDAC patients within the overall PC population - To characterize PDAC patients at diagnosis, with a focus on demographics and tumor-specific characteristics, and assess the proportion of patients with metastatic PDAC - To describe real‑world treatment patterns for metastatic PDAC over time, including the use of systemic therapies - To assess overall survival (OS) and progression-free survival (PFS) of metastatic PDAC

2026-10-01T00:00:00Z PharmaLex GmbH, Bad Homburg vor der Höhe http://edoc.rki.de/176904/14031 2026-10-08T14:11:46Z 2026-10-01T00:00:00Z

Diagnosis Stage and Treatment Landscape of Patients with Malignant Melanoma in Germany: A Retrospective Descriptive Analysis of Cancer Registry Data from 2020–2024 PharmaLex GmbH, Bad Homburg vor der Höhe This research project is designed as a retrospective, descriptive analysis of anonymized routine data from clinical cancer registries in Germany. The study will include adult patients with a primary diagnosis of malignant melanoma of the skin (ICD-10-GM code C43) diagnosed between 2020 and 2024. The project aims to generate contemporary real-world evidence on the stage distribution and treatment pathways of patients with malignant melanoma in Germany. The analysis will describe disease stage at initial diagnosis and over time using the staging information available in the registry data, including UICC stage, TNM categories, and supplementary free-text entries for other classification systems. In addition, the study will characterize documented surgical and local treatment measures, including excision of the primary tumor, residual status, lymphadenectomy, and radiotherapy. A further objective is to describe neoadjuvant and adjuvant systemic therapies after excision of the primary tumor, stratified by residual status, including documented treatment classes and substances such as anti-PD-1 antibodies and BRAF/MEK inhibitors. By linking staging information with documented treatment variables, the project seeks to reconstruct clinically meaningful patient groups and describe real-world treatment patterns in relation to disease stage. The findings are intended to improve understanding of the current care situation for patients with malignant melanoma in Germany, provide insight into the implementation of stage-adapted treatment strategies in routine clinical practice, and identify potential areas for further research.

2026-10-01T00:00:00Z